Prognostic significance of NLRP-3 expression in solid cancers: a systematic review and meta-analysis.

Ann MedAug 20, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Nishant Thakur, Muhammad Alamgeer, Manu Kumar et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the prognostic significance of NLRP-3 expression in patients with solid cancers. The analysis revealed that higher NLRP-3 expression correlates with larger tumor size, advanced tumor grade, and poor overall survival (OS) with a hazard ratio of 2.12 (95% CI = 1.49-3.03, p < 0.0001).

Key findings

  • High NLRP-3 expression is associated with poor overall survival (HR: 2.12, 95% CI = 1.49-3.03, p < 0.0001).
  • Patients with high NLRP-3 expression have a worse disease-free survival (HR: 1.86, 95% CI = 1.30-2.65, p = 0.0007).
  • Subgroup analysis shows high NLRP-3 expression correlates with worse OS in head and neck cancer (HR: 2.77, 95% CI = 1.88-4.09, p < 0.00001).
  • In pancreatic cancer, high NLRP-3 expression is linked to poor outcomes (HR: 3.19, 95% CI = 1.73-5.91, p = 0.0002).

Why it matters

Understanding the role of NLRP-3 in cancer progression can help clinicians identify patients at higher risk for poor outcomes, potentially guiding treatment decisions and monitoring strategies.

Source

PubMed · PMID 42625285Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.